Regeneron will not acquire 23andMe’s telehealth subsidiary, Lemonaid Health, which the company purchased for approximately $400 million in 2021.

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

After Foley Hoag’s prior updates regarding the chapter 11 bankruptcy cases of 23andMe Holding Co and its affiliated debtors ...

Me Holding said Tuesday that a U.S. bankruptcy court has approved the sale of “substantially all” its assets to TTAM Research Institute, a California-based nonprofit led by company co-founder and ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

Regeneron acquires 23andMe for $256M following bankruptcy auction Regeneron will take over key assets including 23andMe’s Personal Genome Service, Biobank, Total Health, and research operations, ...

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...